Morgan Stanley
VERV

Morgan Stanley’s Verve Therapeutics VERV Stock Holding History

Morgan Stanley’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-507,127
Closed -$5.7M – 8386
2025
Q2 		$5.7M Sell
507,127
-416,545
-45% -$2.37M ﹤0.01% 3953
2025
Q1 		$4.22M Buy
923,672
+124,731
+16% +$836K ﹤0.01% 4069
2024
Q4 		$4.51M Sell
798,941
-114,250
-13% -$644K ﹤0.01% 4087
2024
Q3 		$4.42M Buy
913,191
+289,461
+46% +$1.68M ﹤0.01% 4053
2024
Q2 		$3.04M Sell
623,730
-261,836
-30% -$1.65M ﹤0.01% 4272
2024
Q1 		$11.8M Buy
885,566
+191,764
+28% +$2.54M ﹤0.01% 3210
2023
Q4 		$9.67M Buy
693,802
+397,574
+134% +$4.93M ﹤0.01% 3945
2023
Q3 		$3.93M Sell
296,228
-45,826
-13% -$738K ﹤0.01% 3923
2023
Q2 		$6.41M Buy
342,054
+101,233
+42% +$1.69M ﹤0.01% 3571
2023
Q1 		$3.47M Buy
240,821
+143,878
+148% +$2.82M ﹤0.01% 4080
2022
Q4 		$1.88M Sell
96,943
-35,383
-27% -$937K ﹤0.01% 4510
2022
Q3 		$4.54M Sell
132,326
-65,220
-33% -$2.08M ﹤0.01% 3778
2022
Q2 		$3.02M Sell
197,546
-19,226
-9% -$298K ﹤0.01% 4203
2022
Q1 		$4.95M Buy
216,772
+199,616
+1,164% +$5.7M ﹤0.01% 3697
2021
Q4 		$632K Buy
17,156
+11,267
+191% +$473K ﹤0.01% 5403
2021
Q3 		$276K Buy
5,889
+3,421
+139% +$201K ﹤0.01% 5826
2021
Q2 		$149K Buy
+2,468
New +$102K ﹤0.01% 6164

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's VERV Position: Q3 2025 in Review

Morgan Stanley sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 507,127 shares — an estimated $5.7M sold.

Morgan Stanley first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $11.8M in Q1 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Morgan Stanley reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 507,127 Verve Therapeutics shares in Q3 2025, an estimated $5.7M.
  • Morgan Stanley first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Morgan Stanley's Verve Therapeutics position peaked at $11.8M in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.